Eleni T. Tzavara

TL;DR: Investigation of the behavioural effects of morphine reveals that a lack of μ receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence, and concludes that the µ-opioid-receptor gene product is a mandatory component of the opioid system for morphine action.

TL;DR: In mice with a genetic deletion of DAR PP-32 or with point mutations in phosphorylation sites of DARPP-32, the effects of D-amphetamine, LSD, and PCP on two behavioral parameters—sensorimotor gating and repetitive movements—were strongly attenuated.

TL;DR: CREB-dependent gene transcription is a factor in the onset of behavioral manifestations of opiate dependence and the main symptoms of morphine withdrawal were strongly attenuated.

TL;DR: The results suggest that the cortical selectivity in the release of catecholamines, dopamine in particular, induced by the cannabinoid antagonist SR141716A, its procholinergic properties, together with its mild stimulatory effects on serotonin and norepinephrine efflux make similar compounds unique candidates for the treatment of psychosis, affective and cognitive disorders.

TL;DR: It is shown that, in vivo, fluoxetine, given either acutely or chronically, regulates the phosphorylation state of dopamine- and cAMP-regulated phosphoprotein of Mr 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippocampus, and striatum.